Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 609

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 3
Chunk 609
---
2016 for Patheon N.V. (NYSE: PTHN), a pharmaceutical manufacturing company, until its acquisition by Thermo
Fisher in late 2017. Mr. Hayes holds a Bachelor of Science in accounting from the University of North Carolina at Greensboro. We believe
Mr. Hayes is qualified to serve on our board of directors because of his accounting background and experience serving on public company
boards.

Mark
J. Gilbert has served on our board of directors since November 2021. Dr. Gilbert brings more than 30 years of experience in global
medical and clinical research and development, and management of medical affairs. From March 2019 to March 2022, Dr. Gilbert served as
Executive Vice President of Research and Development at Acepodia, Inc., a clinical-stage biotechnology company addressing gaps in cancer
care and since June 2021, Dr. Gilbert has served as a Clinical Development Advisor to Decoy Biosystems, Inc., the Company’s wholly
owned-subsidiary. In addition, from October 2020 to January 2024, Dr. Gilbert served as the Chairman of the Scientific Advisory Board
at Inceptor Bio, LLC, a biotechnology company developing multiple next- generation cell and gene therapy platforms for underserved and
difficult-to-treat cancers, after January 2024 he remains an SAB member, and from October 2020, he serves as a Strategic Advisor at Kineticos
Ventures, a firm providing advisory services and capital to emerging life sciences firms. Prior to these positions, between November
2013 and January 2020, Dr. Gilbert was the Chief Medical Officer of Juno Therapeutics Inc., a biopharmaceutical company, where he led
the clinical development of some of the first CAR-T cell therapies. Before that, Dr. Gilbert held leadership positions at Bayer Schering
Pharma AG, where he served as Vice President and Head of Global Clinical Development, Therapeutic Area Oncology; Berlex Pharmaceuticals,
Inc., where he served as Vice President of Medical Affairs, Oncology, and Vice President and Head of Global Medical Development Group,
Oncology; and Immunex Corporation, where he served as Senior Medical Director, Clinical Research and Development. Between May 2019
and May 2021, Dr. Gilbert served as an Independent Director of Silicon Therapeutics, Inc., a fully integrated drug design and development
company. Dr. Gilbert earned a Bachelor of Science degree in Biochemistry from the